Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

Add Yahoo as a preferred source to see more of our stories on Google. Baricitinib, a pill typically prescribed for rheumatoid arthritis and alopecia, might help slow the progression of type 1 diabetes ...

Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.

Add Yahoo as a preferred source to see more of our stories on Google. Daily oral GLP-1 pill orforglipron shows strong weight loss and blood sugar gains in two major trials. (CREDIT: Shutterstock) A ...

With the U.S. Food and Drug Administration (FDA) recently approving GLP-1 drug Wegovy in pill form for use in weight loss and fighting obesity, the question arises whether other GLP-1 drugs will also ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist (GLP-1) pill is more effective for weight loss than oral ...

A new experimental treatment may be able to cure type 1 diabetes. About 83% of the patients were able to stop using insulin after the treatment. Research into the treatment is ongoing. Experts explain ...

Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to ...

A daily pill previously shown to slow the progression of type 1 diabetes has now shown a loss of therapeutic benefit when stopped—affirming the promise of the treatment. In 2023, an Australian trial ...

A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib safely preserved the body's own insulin production ...

A growing number of people are searching for weight loss options that feel manageable in daily life. Many of the current treatments rely on injections, which can create their own challenges. Needles, ...